Cardiovascular Systems, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSII research report →
Range $15 – $20
Price Chart
About the company
Cardiovascular Systems, Inc. (CSI) is a medical technology firm dedicated to the creation and commercialization of advanced therapeutic solutions for individuals suffering from peripheral and coronary artery diseases, serving markets both within the United States and internationally. For peripheral artery disease (PAD), CSI offers a range of catheter-based systems designed to treat various types of arterial plaque, including severely calcified deposits, in arteries located both above and below the knee.
- CEO
- Scott Raymond Ward MS
- IPO
- 2006
- Employees
- 725
- HQ
- Saint Paul, MN, US
Get TickerSpark's AI analysis on CSII
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $843.96M
- P/E
- -21.28
- PEG
- 0.80
- P/S
- 3.57
- P/B
- 3.14
- EV/EBITDA
- -26.63
- Div Yield
- 0.00%
- Gross Margin
- 73.14%
- Op Margin
- -15.16%
- Net Margin
- -15.63%
- ROE
- -14.19%
- ROIC
- -12.66%
Latest fiscal year · YoY change
- Revenue
- $236.22M-8.8%
- Gross Profit
- $172.78M-12.7%
- Op Income
- $-35,806,000
- Net Income
- $-36,933,000-175.2%
- EPS
- $-0.94-168.6%
- OCF Growth
- -2645.7%
- FCF Growth
- -488.9%
- 52W High
- $20.00
- 52W Low
- $12.26
- 50D MA
- $19.84
- 200D MA
- $15.84
- Beta
- 0.74
- RSI (14)
- 76
- Avg Volume
- 677.84K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cardiovascular Systems beat consensus in Q1 as coronary growth, international expansion, and new product launches helped offset flat peripheral revenue and ongoing hospital staffing pressure.· November 5, 2022
- Q1 revenue was $59.7 million, up 2% year over year and down 4.5% sequentially; management said results were ahead of consensus.
- Worldwide coronary revenue rose 8% to $20.9 million, helped by support devices and the Scoreflex launch, while peripheral revenue was about flat at $38.8 million.
- Gross margin was 72%; management expects margins to improve sequentially through the year despite inflation and mix pressure.
- International revenue grew 41% to $4.5 million, and CSI is now commercial in 34 countries outside the U.S.
- Management reiterated fiscal 2023 revenue guidance of $255 million to $265 million, or 8% to 12% growth, and expects sequential improvement each quarter.
Q1 revenue was $59.7 million, up 2% year over year and down 4.5% sequentially. Worldwide peripheral revenue was about flat at $38.8 million, while worldwide coronary revenue increased 8% to $20.9 million. U.S. coronary revenue was up 1% to $16.4 million; coronary support product revenue increased 70% to $4.5 million; and outside the U.S. revenue increased 41% to $4.5 million. Gross profit margin was 72% and operating expenses were $53.9 million, up 3%. CSI ended the quarter with $144 million in cash and marketable securities and no long-term borrowings. For fiscal 2023, management reaffirmed revenue guidance of $255 million to $265 million, implying 8% to 12% growth, and said it expects top and bottom line results to improve sequentially each quarter.
Scott Ward said the company is pleased with the business and is seeing momentum across coronary, international, and new product areas. He highlighted Scoreflex, JADE balloons, and the 2.0 Max Crown launch as important growth drivers, and said the company is broadening and diversifying its pipeline. His tone was confident, especially around the revenue outlook, product adoption, and the long-term opportunity in new therapeutic areas.
Jeff Points said Q1 revenue was in line with historical seasonality and reiterated that the quarter was consistent with expectations. He pointed to a 72% gross margin, noting pressure from mix, higher ISD/international/OBL revenue, and freight costs, but said gross margin should improve sequentially over the rest of the fiscal year. He also said CSI had $144 million in cash and marketable securities, no long-term debt, and that the larger Q1 cash use was expected and mostly operational. Guidance was reaffirmed at $255 million to $265 million in revenue, with assumptions of gradual U.S. hospital recovery and sequential improvement across the year.
Analysts focused on peripheral ASP pressure, gross margin expansion, and reimbursement changes in the OBL setting. Management said ASP erosion was mainly in OBL, while hospital ASPs were stable, and said the OBL pricing pressure was beginning to stabilize. They also said hospital staffing shortages continue to defer some peripheral cases and may be accelerating migration to OBLs, but they were cautious about assuming that trend will persist. On the 2.0 Max Crown, management said early feedback has exceeded expectations and that the product addresses a roughly $200 million above-the-knee market that CSI had not previously served.
The call showed multiple growth engines working at once: 8% coronary growth, 41% international growth, and strong early uptake of Scoreflex and 2.0 Max Crown. Management also sounded confident that hospital staffing should gradually improve, gross margin should expand sequentially, and pipeline milestones remain on track.
Peripheral revenue was flat, hospital staffing shortages are still disrupting procedural volume, and management said the macro environment remains unsettled. There was also continued price erosion in OBL, a 12% decline in coronary OAS units versus last year, and some uncertainty around how long migration to OBL can continue or when IVL reimbursement may change.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.9%
- Shares Outstanding
- 42.20M
- Float Shares
- 40.46M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CSII, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parametric Portfolio Associates LLC | 301.07K | ▲ 201.85K |
| Parian Global Management LP | 22.00K | ▲ 22.00K |
| Amalgamated Financial Corp. | 19.64K | ▲ 19.64K |
| Eaton Vance Management | 13.40K | ▼ 108 |
| Sargent Bickham Lagudis LLC | 100 | 0 |
Held by 4 ETFs
Biggest fund positions in CSII by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 23 | Paulsen Erik | sell | 700 |
| Apr 27, 23 | Paulsen Erik | sell | 20,627 |
| Apr 27, 23 | Points Jeffrey S. | sell | 138,957 |
| Apr 27, 23 | Points Jeffrey S. | sell | 34,051 |
| Apr 27, 23 | Rempe Stephen J. | sell | 75,659 |
| Apr 27, 23 | Rempe Stephen J. | sell | 8,561 |
| Apr 27, 23 | Sedo Sandra | sell | 81,881 |
| Apr 27, 23 | Sedo Sandra | sell | 32,503 |
| Apr 27, 23 | Aronson Martha Goldberg | sell | 29,816 |
| Apr 27, 23 | Aronson Martha Goldberg | sell | 12,411 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CSII coverage
Recent articles, reports, and earnings notes.
No research on CSII yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSII report →Cytek Biosciences Set to Join S&P SmallCap 600
prnewswire.com · Apr 25
Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment
zacks.com · Apr 5
Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial
businesswire.com · Apr 3
Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial
businesswire.com · Apr 3
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII
businesswire.com · Mar 29
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII
businesswire.com · Mar 29
Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes
zacks.com · Mar 20
Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors
seekingalpha.com · Feb 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.